ACM
RYTM icon

ADAR1 Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

ADAR1 Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,000
Closed -$46K – 286
2023
Q4 		$46K Buy
+1,000
New +$31.5K 0.02% 116

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ADAR1 Capital Management's RYTM Position: Q1 2026 in Review

ADAR1 Capital Management increased its Rhythm Pharmaceuticals (RYTM) stake by 312% in Q1 2026, buying an estimated $15.6M and bringing the position to 211,450 shares worth $18.4M. The position accounts for 1.08% of the portfolio, ranked #19.

ADAR1 Capital Management first reported a position in RYTM in Q1 2024 and has held it in 8 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • ADAR1 Capital Management held 211,450 shares of Rhythm Pharmaceuticals worth $18.4M as of Q1 2026.
  • ADAR1 Capital Management bought 160,101 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $15.6M.
  • Rhythm Pharmaceuticals made up 1.08% of ADAR1 Capital Management's portfolio in Q1 2026, its #19 holding.
  • ADAR1 Capital Management first reported a position in Rhythm Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.